Compounded GLP-1 FDA Warning Letter Response

The situation

A small telehealth weight-loss company gets an FDA warning letter flagging their website's "generic version of Ozempic" language as misleading, even though every individual statement on the page is technically accurate, the FDA says the overall impression misleads consumers into thinking it's FDA-equivalent. They have 15 days to respond and fix it, or risk seizure of their product inventory, and no idea how to build a response that will actually satisfy the FDA's specific legal theory.

Who receives this

Small weight-loss clinics, med spas, and telehealth companies that market compounded GLP-1 medications and receive an FDA warning letter.

Why the agency will not advise you

The FDA cannot advise the recipient on how to fix its own violation; the entire existing response ecosystem is law-firm analysis explaining the crackdown to an industry audience, not a self-serve tool for the specific business that just got a letter with a 15-day clock running.

Key facts, with sources

• The FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications on September 16, 2025; 30 more warning letters to telehealth companies specifically over compounded semaglutide/tirzepatide marketing claims on February 20, 2026; and 25 additional warning letters to telehealth companies the week of June 15, 2026, three separate, escalating waves within roughly nine months, described by industry press as the largest single enforcement action in GLP-1 history. Recipients have 15 days to respond and correct violations or face potential enforcement actions including product seizure or injunctions. Source: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s — FDA · FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters — Fierce Pharma
• FDA's enforcement theory rests on the 'misleading net impression' doctrine, marketing that, taken as a whole, could cause consumers to believe a compounded product is FDA-approved, FDA-reviewed, or otherwise equivalent to an approved drug, even where individual statements are technically accurate, targeting phrases like 'same active ingredient as Ozempic' or 'generic Zepbound.' As of May 21, 2026, FDA had logged more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. No self-serve response tool for a business that has received a warning letter was found; all available content is legal/industry advisory analysis. Source: FDA's Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters — Sheppard Mullin · FDA's Latest GLP-1 Crackdown: What Compounders and Telehealth Platforms Need to Know — Venable LLP

When to bring in a professional

Self-serve responses fit routine cases: clear facts, amounts a business can absorb, and a deadline still ahead of you. Bring in a licensed professional when the amount at stake is large relative to their fee, the facts are genuinely disputed, criminal exposure is possible, or the deadline has already passed. A short paid consultation to sanity-check your plan is often worth it even when you handle the filing yourself.

All sources for this guide

1. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s — FDA
2. FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters — Fierce Pharma
3. FDA's Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters — Sheppard Mullin
4. FDA's Latest GLP-1 Crackdown: What Compounders and Telehealth Platforms Need to Know — Venable LLP